Skip to main content
Have a personal or library account? Click to login
Biophysical reasons for the variability in detecting cancer biomarkers: the overlooked role of protein–lipid interactions Cover

Biophysical reasons for the variability in detecting cancer biomarkers: the overlooked role of protein–lipid interactions

Open Access
|Oct 2026
Read online

References

  1. Giamougiannis P, Martin-Hirsch PL, Martin FL. The evolving role of MUC16 (CA125) in the transformation of ovarian cells and the progression of neoplasia. Carcinogenesis 2021; 42(3): 327-343.
  2. Piñero F, Dirchwolf M, Pessôa MG. Biomarkers in hepatocellular carcinoma: diagnosis, prognosis and treatment response assessment. Cells 2020; 9(6): 1370.
  3. Adamczyk B, Tharmalingam T, Rudd PM. Glycans as cancer biomarkers. Biochim Biophys Acta 2012; 1820(9): 1347-1353.
  4. Silsirivanit A. Glycosylation markers in cancer. Adv Clin Chem 2019; 89: 189-213.
  5. Lee HH, Wang YN, Xia W, Chen CH, Rau KM, Ye L, Wei Y, Chou CK, Wang SC, Yan M, Tu CY, Hsia TC, Chiang SF, Chao KSC, Wistuba II, Hsu JL, Hortobagyi GN, Hung MC. Removal of N-linked glycosylation enhances PDL1 detection and predicts anti-PD-1/PD-L1 therapeutic efficacy. Cancer Cell 2019; 36(2): 168-178.e4.
  6. Dunbar C, Kushnir MM, Yang YK. Glycosylation profiling of the neoplastic biomarker alpha fetoprotein through intact mass protein analysis. J Proteome Res 2023; 22(1): 226-234.
  7. Khalil-Mgharbel A, Polena H, Dembélé PK, Hasan Sohag MM, Alcaraz JP, Martin DK, Vilgrain I. A biomimetic lipid membrane device reveals the interaction of cancer biomarkers with human serum lipidic moieties. Biotechnol J 2018; 13(12): e1800463.
  8. Pearce OMT. Cancer glycan epitopes: biosynthesis, structure and function. Glycobiology 2018; 28(9): 670-696.
  9. Reily C, Stewart TJ, Renfrow MB, Novak J. Glycosylation in health and disease. Nat Rev Nephrol 2019; 15(6): 346-366.
  10. Feingold KR. Introduction to lipids and lipoproteins. In: Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hamilton E, Hofland J, Jan de Beur S, Kalra S, Kaltsas G, Kapoor N, Kim M, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. Updated 2024 Jan 14.
  11. Ghebosu RE, Pendiuk Goncalves J, Wolfram J. Extracellular vesicle and lipoprotein interactions. Nano Lett 2024; 24(1): 1-8.
  12. Quehenberger O, Armando AM, Brown AH, Milne SB, Myers DS, Merrill AH, Bandyopadhyay S, Jones KN, Kelly S, Shaner RL, Sullards CM, Wang E, Murphy RC, Barkley RM, Leiker TJ, Raetz CR, Guan Z, Laird GM, Six DA, Russell DW, McDonald JG, Subramaniam S, Fahy E, Dennis EA. Lipidomics reveals a remarkable diversity of lipids in human plasma. J Lipid Res 2010; 51(11): 3299-3305.
  13. Nieuwland R, Siljander PRM. A beginner’s guide to study extracellular vesicles in human blood plasma and serum. J Extracell Vesicles 2024; 13(1): e12400.
  14. Nordestgaard BG, Langsted A, Mora S, Kolovou G, Baum H, Bruckert E, Watts GF, Sypniewska G, Wiklund O, Borén J, Chapman MJ, Cobbaert C, Descamps OS, von Eckardstein A, Kamstrup PR, Pulkki K, Kronenberg F, Remaley AT, Rifai N, Ros E, Langlois M; European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine joint consensus initiative. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J 2016; 37(25): 1944-1958.
  15. Rosenson RS, Brewer HB Jr, Ansell BJ, Barter P, Chapman MJ, Heinecke JW, Kontush A, Tall AR, Webb NR. Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat Rev Cardiol 2016; 13(1): 48-60.
  16. Zhang Z, Wang W, Kong P, Feng K, Liu C, Sun T, Sang Y, Duan X, Tao Z, Liu W. New insights into lipid metabolism and prostate cancer. Int J Oncol 2023; 62(6): 74.
  17. Romo EZ, Zivkovic AM. Glycosylation of HDL-associated proteins and its implications in cardiovascular disease diagnosis, metabolism and function. Front Cardiovasc Med 2022; 9: 928566.
  18. Krishnan S, Shimoda M, Sacchi R, Kailemia MJ, Luxardi G, Kaysen GA, Parikh AN, Ngassam VN, Johansen K, Chertow GM, Grimes B, Smilowitz JT, Maverakis E, Lebrilla CB, Zivkovic AM. HDL glycoprotein composition and site-specific glycosylation differentiates between clinical groups and affects IL-6 secretion in lipopolysaccharide-stimulated monocytes. Sci Rep 2017; 7: 43728.
  19. Barletti B, König M, Paracini N, Fragneto G, Alcaraz JP, Nelson A, Vilgrain I, Martin DK, Lolicato F, Maccarini M. How lipid composition shapes the nanostructural interaction of tumor biomarker alpha-fetoprotein and bovine serum albumin with model membranes. J Colloid Interface Sci 2026; 708: 139753.
  20. Moremen KW, Tiemeyer M, Nairn AV. Vertebrate protein glycosylation: diversity, synthesis and function. Nat Rev Mol Cell Biol 2012; 13(7): 448-462.
  21. Čaval T, Heck AJR, Reiding KR. Meta-heterogeneity: evaluating and describing the diversity in glycosylation between sites on the same glycoprotein. Mol Cell Proteomics 2021; 20: 100010.
  22. Woods RJ. Predicting the structures of glycans, glycoproteins, and their complexes. Chem Rev 2018; 118(17): 8005-8024.
  23. Petrescu AJ, Milac AL, Petrescu SM, Dwek RA, Wormald MR. Statistical analysis of the protein environment of N-glycosylation sites: implications for occupancy, structure, and folding. Glycobiology 2004; 14(2): 103-114.
  24. Wang YN, Lee HH, Hsu JL, Yu D, Hung MC. The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis. J Biomed Sci 2020; 27(1): 77.
  25. Napoletano C, Steentoft C, Battisti F, Ye Z, Rahimi H, Zizzari IG, Dionisi M, Cerbelli B, Tomao F, French D, d’Amati G, Panici PB, Vakhrushev S, Clausen H, Nuti M, Rughetti A. Investigating patterns of immune interaction in ovarian cancer: probing the O-glycoproteome by the macrophage galactose-like C-type lectin (MGL). Cancers (Basel) 2020; 12(10): 2841.
  26. Hanif H, Ali MJ, Susheela AT, Khan IW, Luna-Cuadros MA, Khan MM, Lau DTY. Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma. World J Gastroenterol 2022; 28(2): 216-229.
  27. Polley A, Orłowski A, Danne R, Gurtovenko AA, Bernardino de la Serna J, Eggeling C, Davis SJ, Róg T, Vattulainen I. Glycosylation and lipids working in concert direct CD2 ectodomain orientation and presentation. J Phys Chem Lett 2017; 8(5): 1060-1066.
  28. Li XL, Yan ZS, Ma YQ, Ding HM. Impact of glycosylation of apolipoprotein D on its interaction with gold nanoparticles: insights from molecular dynamics simulations. ACS Appl Mater Interfaces 2025; 17(3): 4490-4501.
  29. Rabbani N, Ashour A, Thornalley PJ. Mass spectrometric determination of early and advanced glycation in biology. Glycoconj J 2016; 33(4): 553-568.
  30. Barletti B, Paracini N, Fragneto G, Alcaraz JP, Nelson A, Vilgrain I, Martin DK, Maccarini M. Glycation enhances protein association with lipid bilayer membranes. Langmuir 2025; 41(46): 31169-31178.
  31. Masson D, Jiang XC, Lagrost L, Tall AR. The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis. J Lipid Res 2009; 50(Supp1): S201-S206.
  32. Ginsberg HN, Packard CJ, Chapman MJ, Borén J, Aguilar-Salinas CA, Averna M, Ference BA, Gaudet D, Hegele RA, Kersten S, Lewis GF, Lichtenstein AH, Moulin P, Nordestgaard BG, Remaley AT, Staels B, Stroes ESG, Taskinen MR, Tokgözoğlu LS, Tybjaerg-Hansen A, Stock JK, Catapano AL. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society. Eur Heart J 2021; 42(47): 4791-4806.
  33. Hallal S, Tűzesi Á, Grau GE, Buckland ME, Alexander KL. Understanding the extracellular vesicle surface for clinical molecular biology. J Extracell Vesicles 2022; 11(10): e12260.
  34. Sagini K, Urbanelli L, Buratta S, Emiliani C, Llorente A. Lipid biomarkers in liquid biopsies: novel opportunities for cancer diagnosis. Pharmaceutics 2023; 15(2): 437.
  35. Nikolac N. Lipemia: causes, interference mechanisms, detection and management. Biochem Med (Zagreb) 2014; 24(1): 57-67.
  36. Saracevic A, Dukic L, Simundic AM. Haemolysis and lipemia interfere with resistin and myeloperoxidase BioVendor ELISA assays. Biochem Med (Zagreb) 2019; 29(2): 020703.
  37. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, Byun J, Vuletic S, Kassim S, Singh P, Chea H, Knopp RH, Brunzell J, Geary R, Chait A, Zhao XQ, Elkon K, Marcovina S, Ridker P, Oram JF, Heinecke JW. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007; 117(3): 746-756.
  38. Ronsein GE, Vaisar T. Deepening our understanding of HDL proteome. Expert Rev Proteomics 2019; 16(9): 749-760.
  39. Vilgrain I, Sidibé A, Polena H, Cand F, Mannic T, Arboleas M, Boccard S, Baudet A, Gulino-Debrac D, Bouillet L, Quesada JL, Mendoza C, Lebas JF, Pelletier L, Berger F. Evidence for post-translational processing of vascular endothelial (VE)-cadherin in brain tumors: towards a candidate biomarker. PLoS One 2013; 8(12): e80056.
  40. Gries A, Prassl R, Fukuoka S, Rössle M, Kaconis Y, Heinbockel L, Gutsmann T, Brandenburg K. Biophysical analysis of the interaction of the serum protein human β2GPI with bacterial lipopolysaccharide. FEBS Open Bio 2014; 4: 432-440.
  41. Calvo D, Gómez-Coronado D, Lasunción MA, Vega MA. CLA-1 is an 85-kD plasma membrane glycoprotein that acts as a high-affinity receptor for both native (HDL, LDL, and VLDL) and modified (OxLDL and AcLDL) lipoproteins. Arterioscler Thromb Vasc Biol 1997; 17(11): 2341-2349.
  42. Park YM. CD36, a scavenger receptor implicated in atherosclerosis. Exp Mol Med 2014; 46(6): e99.
  43. Bartosch B, Verney G, Dreux M, Donot P, Morice Y, Penin F, Pawlotsky JM, Lavillette D, Cosset FL. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J Virol 2005; 79(13): 8217-8229.
  44. Macchioni A, Ciancaleoni G, Zuccaccia C, Zuccaccia D. Determining accurate molecular sizes in solution through NMR diffusion spectroscopy. Chem Soc Rev 2008; 37(3): 479-489.
  45. Kusnezow W, Syagailo YV, Rüffer S, Klenin K, Sebald W, Hoheisel JD, Gauer C, Goychuk I. Kinetics of antigen binding to antibody microspots: strong limitation by mass transport to the surface. Proteomics 2006; 6(3): 794-803.
Language: English
Page range: 323 - 330
Published online: Oct 31, 2026
Published in print: Oct 1, 2026
Published by: European Biotechnology Thematic Network Association
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2026 Beatrice Barletti, Isabelle Vilgrain, Marco Maccarini, Donald K. Martin, published by European Biotechnology Thematic Network Association
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.